This site is intended for healthcare professionals

HeartInsight, a remote heart failure (HF) management solution received CE Mark.

Read time: 1 mins
Published:22nd Mar 2022

Biotronik announced the CE approval for HeartInsight, its remote heart failure (HF) management solution that accurately identifies patients at higher risk of HF decompensation early on.

HeartInsight predicts two out of three HF hospitalizations, coupled with an industry-low false alert rate. Compared to other available solutions, HeartInsight provides the earliest notification, a median advance notice of 42 days before an impending HF hospitalization, which allows clinicians to proactively care for their patients. HeartInsight will be presented to clinicians for the first time at the EHRA Congress which takes place in Copenhagen, Denmark, from April 3 to 5, 2022.

HeartInsight will be available for patients with compatible CRT-D and ICD devices and is integrated into Biotronik’s Home Monitoring platform which displays patient health data that is transmitted from their cardiac implant automatically every day. HeartInsight’s algorithm combines relevant HF parameters into one predictive score and alerts the clinical team that a patient is at higher risk of hospitalization once a pre-set threshold has been crossed. All relevant information is organized in an insightful dashboard, designed for improved collaboration and decision-making.

Condition: Heart Failure
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.